MedTrace Logo

Oscillation and Lung Expansion (OLE) Therapy for Treatment of Neuromuscular Disease (NMD) Patients

NCT05366010 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-07-31

Study results available
· View outcomes & findings →

Summary

The study will be a non-randomized open label pilot study comparing a retrospective control period to an active treatment period with oscillation and lung expansion (OLE) therapy.

Conditions

Interventions

DEVICE

Oscillation and Lung Expansion (OLE) therapy

Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure

Sponsors & Collaborators

  • Science 37

    collaborator INDUSTRY

  • Baxter Healthcare Corporation

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-04
Primary Completion
2024-02-27
Completion
2024-02-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05366010 on ClinicalTrials.gov